{"schema_version":"secwatch.filing_event.v1","accession":"0000921895-21-001834","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2021-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.746212+00:00","generated_at":"2026-06-30T06:22:40.296430+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"CFO Michael Donaldson departs; Duggan interim CFO, Maranian accounting officer","bullets":["Michael Donaldson departed as CFO effective July 2, 2021.","Robert W. Duggan (CEO & Executive Chairman) appointed interim principal financial officer.","Jeffrey R. Maranian (Corporate Controller since Nov 2020) appointed principal accounting officer."],"urls":{"canonical":"https://secwatch.observer/filing/0000921895-21-001834","json":"https://secwatch.observer/filing/0000921895-21-001834.json","markdown":"https://secwatch.observer/filing/0000921895-21-001834.md","text":"https://secwatch.observer/filing/0000921895-21-001834.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000092189521001834/0000921895-21-001834-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000092189521001834/form8k12566003_07082021.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T06:22:40.296430+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b9f5c71cf5","claim":"Jeffrey R. Maranian was appointed as principal accounting officer at Summit Therapeutics Inc..","evidence_excerpt":"the board of directors (the “Board”) of the Company appointed Robert W. Duggan to serve as interim principal financial officer and Jeffrey R. Maranian to serve as principal accounting officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1599298/000092189521001834/0000921895-21-001834-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"principal accounting officer"}],"fact_type":"executive_change"},{"claim_id":"c5c7d8cbc1","claim":"Michael Donaldson departed as Chief Financial Officer at Summit Therapeutics Inc..","evidence_excerpt":"Effective on July 2, 2021 in connection with the departure of Michael Donaldson as Chief Financial Officer of Summit Therapeutics Inc. (the “Company”),","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1599298/000092189521001834/0000921895-21-001834-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"departed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"cb0222c58b","claim":"Robert W. Duggan was appointed as interim principal financial officer at Summit Therapeutics Inc..","evidence_excerpt":"the board of directors (the “Board”) of the Company appointed Robert W. Duggan to serve as interim principal financial officer and Jeffrey R. Maranian to serve as principal accounting officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1599298/000092189521001834/0000921895-21-001834-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim principal financial officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}